Managing BTK inhibitor treatment-related adverse events in patients with chronic lymphocytic leukaemia – cardiovascular complications and bleeding
Authors:
A. Panovská 1; T. Arpáš 1; M. Šimkovič 2; M. Špaček 3; T. Papajík 4; D. Lysák 5; L. Bezděková 1; M. Doubek 1
Authors‘ workplace:
Interní hematologická a onkologická klinika LF MU a FN Brno
1; IV. interní hematologická klinika LF UK a FN Hradec Králové
2; I. interní klinika – klinika hematologie I. LF UK a VFN v Praze
3; Hemato-onkologická klinika LF UP a FN Olomouc
4; Hematologicko-onkologické oddělení FN Plzeň
5
Published in:
Transfuze Hematol. dnes,29, 2023, No. 3, p. 177-184.
Category:
doi:
https://doi.org/10.48095/cctahd2023prolekare.cz12
Overview
Bruton’s tyrosine kinase (BTK) inhibitors have altered the treatment landscape of chronic lymphocytic leukaemia (CLL). These highly eff ective drugs improve not only the prognosis but also the quality of life of CLL patients. Long-term BTK inhibitor treatment can be limited by specifi c adverse events (AEs) such as cardiovascular (CV) complications or bleeding. Ibrutinib, the fi rst-in-class BTK inhibitor, was discontinued in up to 26% of patients in clinical trials due to AEs. Therefore, there are continuing eff orts to develop BTK inhibitors with the same eff ectivity but better safety profi le, such as covalent BTKi acalabrutinib and zanubrutinib and non-covalent BTKi pirtobrutinib and nemtabrutinib. The pre-treatment workup for all patients should include CV risk level assessment using scoring systems, e. g., Framingham risk score or SCORE. In patients with high CV risk levels, next-generation BTK inhibitors or other targeted drugs (venetoclax or idelalisib) are generally preferred over ibrutinib. Patients who experience CV toxicity, particularly atrial fi brillation or heart failure, should be consulted with a cardiologist to defi ne the best treatment algorithm. In contrast to CV toxicity, the risk of major bleeding events is equal for both ibrutinib and acalabrutinib (2–9% vs. 2–5%) based on data from clinical trials. Regarding prevention of bleeding events, BTK inhibitor treatment should be appropriately held prior to any invasive procedure and cannot be restarted until the risk of bleeding is minimal. Good knowledge of the patient’s current medication and potential interactions is crucial in the prevention of any adverse event. This review describes the mechanisms of pathogenesis of cardiovascular complications and bleeding in BTK inhibitor-treated patients. It summarises their incidence in selected clinical trials and provides recommendations for managing these AEs in clinical practice.
Keywords:
bleeding – ibrutinib – arterial hypertension – chronic lymphocytic leukaemia – acalabrutinib – BTK inhibitor – atrial fi brillation
Sources
1. Smolej L, Špaček M, Pospíšilová Š, et al. Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie 2021. Transfuze Hematol Dnes. 2021; 27 (1): 91–106.
2. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015; 373: 2425–2437.
3. Byrd JC, Furman RR, Coutre SE, et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res. 2020; 26: 3918–3927.
4. Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021; 39 (31): 3441–3452.
5. O’Brien SM, Brown JR, Byrd JC, et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol. 2021; 11: 720704.
6. Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Eng J Med. 2023; 388: 319–332.
7. Mato AR, Woyach JA, Brown JR, et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: additional patients and extended follow-up from phase 1/2 BRUIN study. Blood. 2022; 140 (Suppl 1): 2316–2320.
8. Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019; 94 (12): 1353–1363.
9. Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020; 34 (3): 787–798.
10. Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022; 36: 1171–1175.
11. Jones JA, Hillmen P, Coutre S, et al. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017; 178: 286–291.
12. Awan FT, Addison D, Alfraih F, et al. International consensus statement on management of cardiovascular risk of Bruton‘s tyrosine kinase inhibitors in CLL. Bood Adv. 2022; 6 (18): 5516–5524.
13. Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020; 1: 336–345.
14. Bitton A, Gaziano T. The Framigham Hear Study’s impact on global risk assessment. Prog Cardiovasc Dis. 2010; 53: 6878.
15. Zikmund Galková L, Špinar J, Ludka O. Skórovací systémy preventivní kardiologie. Kardiol Rev Int Med. 2015; 17 (2): 112–116.
16. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Hear J. 2003; 24: 1601–1610.
17. Cífková R, Býma S, Češka R, et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Cor Vasa. 2005; 47 (Suppl): 3–14.
18. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137 (2): 263–272.
19. Pisters R, Lane DA, Nieuwlaat R, et al. Novel user friendly score (Has-Bled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest. 2010; 138 (5): 1093–1100.
20. Brown JR. How I treat CLL patients with ibrutinib. Blood. 2018; 131 (4): 379–386.
21. Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019; 133 (12): 1298–1307.
22. Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice; the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016; 23 (11): NP1–NP96.
23. Lyon AR, López-Fernandéz T, Couch LS, et al. Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic RAdiology and Oncology (ESTRO) and the International Cardio-Oncology Sociery (IC-OS). Eur Heart J. 2022; 43: 4229–4361.
24. Quek LS, Bolej J, Watson SP. A role for Bruton’s tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol CB. 1998; 8 (20): 1137–1140.
25. Kamel S, Horton L, Yserbat L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015; 29 (4): 783–787.
26. Lipsky AH, Farooqui MZH, Tian X, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015; 100 (12): 1571–1578.
27. Dobie G, Kuriri FA, Omar MMA, et al. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin aIIbß3 in mice and humans. Blood Adv. 2019; 3 (24): 4298–4311.
28. Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding; pathogenesis, management, and risk reduction strategies. J Thromb Haemost. 2017; 15 (5): 835–847.
29. Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015; 29: 783–787.
30. Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014; 124: 3991–3995.
31. Byrd JC, Brown JR, O’BrienS, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia. N Eng J Med. 2014; 371 (3): 213–223.
32. O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17 deletion (RESONATE17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016; 17 (10): 1409–1418.
33. Wang ML, Blum KA, Martin P, et al. Long term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015; 126: 739–745.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2023 Issue 3
Most read in this issue
- Hereditary haemorrhagic teleangiectasia (Rendu-Osler-Weber disease)
- Boris Bubeník slaví sedmdesátiny
- Managing BTK inhibitor treatment-related adverse events in patients with chronic lymphocytic leukaemia – cardiovascular complications and bleeding
- Covid score – the contribution in prognostic stratification of patients with COVID-19